0001564590-21-011758 Sample Contracts
AMENDMENT #6 TO LICENSE AGREEMENTLicense Agreement • March 9th, 2021 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This Amendment #6 to License Agreement (“Amendment #6”) is entered into as of the date of last signature below (“Amendment #6 Effective Date”) by and between Merck Sharp & Dohme Corp. (formerly known as Schering Corporation), a New Jersey corporation having a place of business at 2000 Galloping Hill Road, Kenilworth, NJ 07033 (“Merck”) and Eiger BioPharmaceuticals, Inc., a Delaware corporation having a place of business at 350 Cambridge Avenue, Suite 350, Palo Alto, CA 94306 (“Licensee”) (each of Merck and Licensee, a “Party”, and together, the “Parties”) to amend that certain License Agreement between the Parties dated September 3, 2010, as amended on January 18, 2011 and subsequently first amended June 11, 2013, as second amended November 20, 2014, as third amended March 6, 2015, as fourth amended June 9, 2015, and as fifth amended December 15, 2015 (collectively, the “Agreement”).
Standard Contracts
FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 9th, 2021 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
THIS FIFTH AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of February [__], 2021, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (“Parent”), EB Pharma, LLC, a Delaware limited liability company (“EB Pharma”) and EBPI Merger, Inc., a Delaware corporation (“EBPI”), each with offices located at 2155 Park Blvd., Palo Alto, CA 94306 (Parent, EB Pharma and EBPI, individually and collectively, jointly and severally, “Borrower”).
LICENSE AGREEMENT between EIGER BIOPHARMACEUTICALS, INC. and BRISTOL-MYERS SQUIBB COMPANYLicense Agreement • March 9th, 2021 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
AMENDMENT #7 TO LICENSE AGREEMENTLicense Agreement • March 9th, 2021 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances)
This Amendment #7 to License Agreement (“Amendment #7”) is entered into as of the date of last signature below (“Amendment #7 Effective Date”) by and between Merck Sharp & Dohme Corp. (formerly known as Schering Corporation), a New Jersey corporation having a place of business at 2000 Galloping Hill Road, Kenilworth, NJ 07033 (“Merck”) and Eiger BioPharmaceuticals, Inc., a Delaware corporation having a place of business at 2155 Park Boulevard, CA 94306 (“Licensee”) (each of Merck and Licensee, a “Party”, and together, the “Parties”) to amend that certain License Agreement between the Parties dated September 3, 2010, as amended on January 18, 2011 and subsequently first amended June 11, 2013, as second amended November 20, 2014, as third amended March 6, 2015, as fourth amended June 9, 2015, as fifth amended December 15, 2015, as sixth amended on May 15, 2018 (collectively, the “Agreement”).
LICENSE AGREEMENTLicense Agreement • March 9th, 2021 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
THIS LICENSE AGREEMENT (this “Agreement”), dated as of September 3, 2010, is by and between SCHERING CORPORATION, a New Jersey corporation having its principal place of business at 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (hereinafter referred to as “Schering”) and Eiger Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware and having its principal place of business at 3350 W Bayshore Road, Suite 120, Palo Alto, CA 94303 (hereinafter referred to as “Licensee”). Schering and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ASSET PURCHASE AGREEMENT BY AND BETWEEN ABBVIE INC. AND EIGER BIOPHARMACEUTICALS, INC. NOVEMBER 20, 2020Asset Purchase Agreement • March 9th, 2021 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 20, 2020 (the “Effective Date”), by and between ABBVIE INC., a corporation organized under the laws of Delaware (“Buyer”), and EIGER BIOPHARMACEUTICALS, INC., a corporation organized under the laws of Delaware (“Seller”). Buyer and Seller may hereinafter be referred to individually as a “Party” and collectively as the “Parties.”
ASSET PURCHASE AGREEMENT among: EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation; and TRACEY MCLAUGHLIN AND COLLEEN CRAIG Dated as of September 25, 2015Asset Purchase Agreement • March 9th, 2021 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • California
THIS ASSET PURCHASE AGREEMENT is entered into, effective as of September 25, 2015 (the “Effective Date”), by and between EIGER BIOPHARMACEUTICALS, INC., a Delaware corporation (“Purchaser”) and TRACEY MCLAUGHLIN AND COLLEEN CRAIG (each individually, “Seller”, collectively, “Sellers”). Purchaser and Sellers are referred to herein collectively as the “Parties” and individually as a “Party.” Certain other capitalized terms used in this Agreement are defined in Exhibit A.
COLLABORATION AND SUPPLY AGREEMENTCollaboration and Supply Agreement • March 9th, 2021 • Eiger BioPharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
This Collaboration and Supply Agreement (“Agreement”) is made and entered into as of May 15, 2018 (the “Effective Date”) by and between Eiger BioPharmaceuticals, Inc., a Delaware corporation having a place of business at 350 Cambridge Avenue, Suite 350, Palo Alto, CA 94306 (“Eiger”), and The Progeria Research Foundation, Inc., a 501(c)(3) not-for-profit organization currently located at 200 Lake St., Peabody MA 01960 (“PRF”). Eiger and PRF are individually referred to as a “Party” and collectively referred to as the “Parties.”
